Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Ceos Condemn Political Violence After Trump Shooting

170 major CEOs unite to denounce political violence after Trump shooting, emphasizing peace and unity.

Top News

Here's What to Expect From Pfizer’s Next Earnings Report

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

Barchart

1 Big Pharma Dividend Stock to Snag While It's Still Cheap

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer to move daily weight-loss pill to clinical trials

Firm says drug Danuglipron has shown ‘encouraging’ signs in early studies

Evening Standard

Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug

Pfizer stock jumped early Thursday after the drugmaker said it selected a once-daily pill to move forward as a potential weight-loss drug.

Investors Business Daily

Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone

Several stocks angled higher early Thursday with one in a buy zone and two looking to reclaim key levels.

Investors Business Daily

3 Value Stocks to Buy and Hold for Passive Income

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Vaccine panel more strongly endorses RSV shots for oldest Americans

Federal advisers are making a stronger endorsement for RSV vaccinations for people 75 and older

The Independent UK

Moderna Dives 11% After RSV Vaccine Proves Less Effective Than Pfizer, GSK Shots

Moderna stock tumbled Wednesday after the company said its newly approved RSV vaccine was only about 50% effective after 18 months.

Investors Business Daily

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

EU Chief's Texts For Covid Vaccines Under Court Scrutiny

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

International Business Times

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.

Investors Business Daily

3 Ultra High-Yield Dividend Stocks to Pounce On at Every Dip

These dividend stocks have consistently paid dividends with yields over 6%.

Barchart

New RSV shots tied to rare nervous system disorder — should you worry?

There's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But health officials still recommend that this population get the shots, in consultation with their doctors.

LiveScience

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test

Sarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy failed in final-phase testing.

Barchart

3 Healthcare Stocks With The Highest Yields As of June 2024

Looking for yield? Here's 3 healthcare stocks with the highest yields today.

The Independent UK

Combined Covid and flu vaccine could be approved for use on NHS by next year

New vaccine could cut need for separate Covid and flu jabs

The Independent UK

FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Should You Buy This S&P 500 Stock with a Dividend Yield of Nearly 6%?

With a dividend yield of nearly 6%, pharma giant Pfizer is among the highest-yielding S&P 500 stocks. While the stock's price action has been disappointing like most other high-dividend stocks, it looks worth a bet given the tepid valuations.

Fortune

Only 49 companies have been on the Fortune 500 for all 70 years. Here are their secrets to staying in power

Prolonged success boils down to a few subtle factors—but surprisingly, they don't include strategy, structure, technology, or even culture.

Salon

Bird flu vaccines face a problem: eggs

Fertilized hen eggs are still the main ingredient in making vaccines that may protect us against H5N1

The Independent UK

Scientists are testing mRNA vaccines to protect cows and people against bird flu

The bird flu outbreak in U.S. dairy cows is prompting development of new, next-generation mRNA vaccines — akin to the shots deployed during the COVID-19 pandemic

Investors Business Daily

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

International Business Times

Strong Trial Results For Pfizer Lung Cancer Drug

A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.

Medical Daily

Guillain-Barre Syndrome 'More Common Than Expected' In RSV Vaccinated Older Adults: CDC

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.